LIG not only suppresses HCC malignancy but also blocks tumor-associated macrophage recruitment and M2 polarization by inhibiting YAP/IL-6-driven activation of IL-6R/STAT3 signaling 5, suggesting therapeutic utility even in advanced, transformation-prone liver diseases. Here, UBE2K is linked to hepatocellular carcinoma.